Clinical Trial Update: Safety and Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION). [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety and efficacy of RPh201 for non-arteritic ischemic optic neuropathy with completed results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-arteritic Ischemic Optic Neuropathy
• Optic Nerve Injuries

Drugs mentioned

• RPh201

Snippet

Sponsor: Regenera Pharma Ltd | Conditions: Non-arteritic Ischemic Optic Neuropathy, Optic Nerve Injuries | Phase 2 | Status: COMPLETED | Results posted: 2019-03-01